Suspicion Juvenile Myelomonocytic Leukemia
Item
patients must have a strong clinical suspicion of jmml, based on a modified category 1 of the revised diagnostic criteria; specifically, eligible patients must have all of the following:
boolean
C0242114 (UMLS CUI [1,1])
C0349639 (UMLS CUI [1,2])
Splenomegaly
Item
splenomegaly
boolean
C0038002 (UMLS CUI [1])
Monocyte count procedure
Item
absolute monocyte count (amc) > 1000/ul
boolean
C0200637 (UMLS CUI [1])
Blasts Peripheral blood Percentage | Blasts Bone Marrow Percentage
Item
blasts in peripheral blood (pb)/bone marrow (bm) < 20%
boolean
C0368761 (UMLS CUI [1,1])
C0229664 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0368761 (UMLS CUI [2,1])
C0005953 (UMLS CUI [2,2])
C0439165 (UMLS CUI [2,3])
Patients Without Splenomegaly | Diagnostic criteria Fulfill
Item
for the 7-10% of patients without splenomegaly, the diagnostic entry criteria must include all other features described above and at least 2 of the following criteria:
boolean
C0030705 (UMLS CUI [1,1])
C0332288 (UMLS CUI [1,2])
C0038002 (UMLS CUI [1,3])
C0679228 (UMLS CUI [2,1])
C1550543 (UMLS CUI [2,2])
Myeloid precursor cell Circulating
Item
circulating myeloid precursors
boolean
C1268007 (UMLS CUI [1,1])
C0175630 (UMLS CUI [1,2])
White Blood Cell Count procedure
Item
white blood cell (wbc) > 10,000/ul
boolean
C0023508 (UMLS CUI [1])
Elevated fetal hemoglobin | Relationship Age
Item
increased fetal hemoglobin (hgbf) for age
boolean
C2751485 (UMLS CUI [1])
C0439849 (UMLS CUI [2,1])
C0001779 (UMLS CUI [2,2])
Hypersensitivity Sargramostim | Prior diagnosis Juvenile Myelomonocytic Leukemia
Item
sargramostim (gm-csf) hypersensitivity or, patients must have been previously diagnosed with jmml
boolean
C0020517 (UMLS CUI [1,1])
C0216231 (UMLS CUI [1,2])
C0332132 (UMLS CUI [2,1])
C0349639 (UMLS CUI [2,2])
Hemopoietic stem cell transplant Absent
Item
patients must be previously untreated with hct
boolean
C0472699 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Informed Consent | Informed Consent Parent | Informed Consent Legal Guardians
Item
all patients and/or their parents or legal guardians must sign a written informed consent
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030551 (UMLS CUI [2,2])
C0021430 (UMLS CUI [3,1])
C0023226 (UMLS CUI [3,2])
Requirement Human studies Fulfill
Item
all institutional, food and drug administration (fda), and national cancer institute (nci) requirements for human studies must be met
boolean
C1514873 (UMLS CUI [1,1])
C0178693 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
Germ-Line Mutation PTPN11 | Noonan Syndrome
Item
patients with a known germline mutation of ptpn11 (noonan's syndrome) are not eligible
boolean
C0206530 (UMLS CUI [1,1])
C1335280 (UMLS CUI [1,2])
C0028326 (UMLS CUI [2])
Neurofibromatosis Type
Item
patients with a known history of nf1 (neurofibromatosis type 1) and either
boolean
C0162678 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
Central Nervous System Neoplasms | Astrocytoma | Optic Nerve Glioma
Item
a history of a tumor of the central nervous system (astrocytoma or optic glioma), or
boolean
C0085136 (UMLS CUI [1])
C0004114 (UMLS CUI [2])
C0346326 (UMLS CUI [3])
Malignant Peripheral Nerve Sheath Tumor Complete remission Duration
Item
a malignant peripheral nerve sheath tumor with a complete remission of < 1 year are not eligible
boolean
C0751690 (UMLS CUI [1,1])
C0677874 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
HIV Seropositivity
Item
human immunodeficiency virus (hiv) positive patients are not eligible
boolean
C0019699 (UMLS CUI [1])